Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE
Sponsored by SMT (Sahajanand Medical Technologies)
STEMI
Stents, scaffolds and DCB
Multivessel disease
Symposium with Recorded case
SMT (Sahajanand Medical Technologies)
Room 251
Anchorperson: Patrick Serruys
Spokesperson: Yoshinobu Onuma
Discussants: Ana Belen Cid Alvarez, Jacek Legutko, Raul Moreno, Helge Möllmann, Ashok Seth, Joanna Wykrzykowska
Guest speakers: Atul Abhyankar, Gianluca Campo, Anuruck Jeamanukoolkit, David Leistner, Tsung-Ying Tsai
Watch this session if you want
- To understand the coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis
- To understand the performance of the Supraflex stent for high-risk patients such as high bleeding risk or the elderly
- To preview the anticipated outcomes of two major randomised trials in patients with triple vessel disease, with or without diabetes
Welcome and session objectives
Patrick Serruys
Two-year follow-up of live case performed in Toulouse: left main bifurcation guided by coronary CT angiography and OCT
Tsung-Ying Tsai
The coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis
Atul Abhyankar
Evidence of Supraflex in high bleeding risk patients: the EARTH HBR study: a pooled analysis of nearly 1000 patients with one-month DAPT from the FIRE, COMPARE60/80, Cruz HBR studies
Gianluca Campo
Evidence of Supraflex in octogenarian patients: the Cruz Senior registry
Pre-recorded case: complex PCI in an elderly patient
Anuruck Jeamanukoolkit
What to expect about Supraflex in 2025: randomised comparison of device success: Synergy vs. Supraflex according to EAPCI criteria
Patrick Serruys
What to expect about Supraflex at the 2025 (teaser): MVT outcome prediction
Yoshinobu Onuma
Discussion and audience interaction
Session evaluation and key learnings
Yoshinobu Onuma
